{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:08:39Z","timestamp":1791216519261,"version":"4.1.0"},"reference-count":64,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82160148"],"award-info":[{"award-number":["82160148"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Fundamental Research Funds for Central Universities","award":["lzujbky-2023-ct06"],"award-info":[{"award-number":["lzujbky-2023-ct06"]}]},{"name":"Gansu Province Joint Research Fund","award":["23JRRA1509"],"award-info":[{"award-number":["23JRRA1509"]}]},{"name":"Gansu Province Major Science and Technology Special Project","award":["24ZDFA007"],"award-info":[{"award-number":["24ZDFA007"]}]},{"name":"Gansu Province Key Talent Program","award":["2023RCXM42"],"award-info":[{"award-number":["2023RCXM42"]}]},{"name":"Cuiying Science and Technology Innovation Program","award":["CY2024-LC-A01"],"award-info":[{"award-number":["CY2024-LC-A01"]}]},{"name":"The Key Incubation Project Funds of the second hospital and clinical medical school","award":["2025-22-zdfy-005, 2025-24-zdfy-019"],"award-info":[{"award-number":["2025-22-zdfy-005, 2025-24-zdfy-019"]}]},{"name":"Gansu Provincial Higher Education Innovation Fund","award":["2023B-045"],"award-info":[{"award-number":["2023B-045"]}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Enzyme Inhibition and Medicinal Chemistry"],"published-print":{"date-parts":[[2026,12,31]]},"DOI":"10.1080\/14756366.2026.2622725","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T11:44:07Z","timestamp":1770723847000},"update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":3,"title":["Integrating virtual screening and molecular dynamics simulations to identify emodin as a PYCR1 inhibitor modulating docetaxel sensitivity in prostate cancer"],"prefix":"10.1080","volume":"41","author":[{"given":"Shuai","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Urology, The Second Hospital and Clinical Medical School, Lanzhou University","place":["Lanzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongfeng","family":"Lao","sequence":"additional","affiliation":[{"name":"Department of Urology, The Second Hospital and Clinical Medical School, Lanzhou University","place":["Lanzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Urology, The Second Hospital and Clinical Medical School, Lanzhou University","place":["Lanzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Urology, The Second Hospital and Clinical Medical School, Lanzhou University","place":["Lanzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longtu","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Urology, The Second Hospital and Clinical Medical School, Lanzhou University","place":["Lanzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyun","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Urology, Gansu Province Clinical Research Center for Urinary System Disease, The Second Hospital and Clinical Medical School, Lanzhou University","place":["Lanzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Urology, The Second Hospital and Clinical Medical School, Lanzhou University","place":["Lanzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxuan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Urology, The Second Hospital and Clinical Medical School, Lanzhou University","place":["Lanzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongze","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Urology, The Second Hospital and Clinical Medical School, Lanzhou University","place":["Lanzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingchao","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Urology, Gansu Province Clinical Research Center for Urinary System Disease, The Second Hospital and Clinical Medical School, Lanzhou University","place":["Lanzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Tao","sequence":"additional","affiliation":[{"name":"Institute of Urology, Gansu Province Clinical Research Center for Urinary System Disease, The Second Hospital and Clinical Medical School, Lanzhou University","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanhui","family":"Liu","sequence":"additional","affiliation":[{"name":"Institute of Urology, Gansu Province Clinical Research Center for Urinary System Disease, The Second Hospital and Clinical Medical School, Lanzhou University","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhilong","family":"Dong","sequence":"additional","affiliation":[{"name":"Department of Urology, Gansu Province Clinical Research Center for Urinary System Disease, The Second Hospital and Clinical Medical School, Lanzhou University","place":["Lanzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,2,10]]},"reference":[{"key":"e_1_3_4_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2021.09.006"},{"issue":"1","key":"e_1_3_4_3_1","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel RL","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA Cancer J Clin. 2025;75(1):10\u201345.","journal-title":"CA Cancer J Clin"},{"issue":"7","key":"e_1_3_4_4_1","first-page":"617","article-title":"[Expert consensus on whole-course management of prostate cancer (2025 edition)]","volume":"47","author":"Genitourinary Oncology Committee of Chinese Anti-Cancer Association","year":"2025","unstructured":"Genitourinary Oncology Committee of Chinese Anti-Cancer Association [Expert consensus on whole-course management of prostate cancer (2025 edition)]. Zhonghua Zhong Liu Za Zhi. 2025;47(7):617\u2013634.","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(18)30127-X"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21763"},{"issue":"27","key":"e_1_3_4_7_1","doi-asserted-by":"crossref","first-page":"3686","DOI":"10.1200\/JCO.2010.34.3996","article-title":"Chemotherapy-based treatment for castration-resistant prostate cancer","volume":"29","author":"Seruga B","year":"2011","unstructured":"Seruga B, Tannock IF. Chemotherapy-based treatment for castration-resistant prostate cancer. J Clin Oncol. 2011;29(27):3686\u20133694.","journal-title":"J Clin Oncol"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040720"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70479-0"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1177\/1758834012449685"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2017.78"},{"issue":"4","key":"e_1_3_4_12_1","first-page":"676","article-title":"Molecular mechanisms of docetaxel resistance in prostate cancer","volume":"3","author":"Sekino Y","year":"2020","unstructured":"Sekino Y, Teishima J. Molecular mechanisms of docetaxel resistance in prostate cancer. Cancer Drug Resist. 2020;3(4):676\u2013685.","journal-title":"Cancer Drug Resist"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.114392"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-10-0343"},{"issue":"26","key":"e_1_3_4_15_1","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1038\/s41388-024-03059-4","article-title":"Targeting the glutamine metabolism to suppress cell proliferation in mesenchymal docetaxel-resistant prostate cancer","volume":"43","author":"Beier A-MK","year":"2024","unstructured":"Beier A-MK, Ebersbach C, Siciliano T, Scholze J, Hofmann J, H\u00f6nscheid P, Baretton GB, Woods K, Guezguez B, Dubrovska A, et al. Targeting the glutamine metabolism to suppress cell proliferation in mesenchymal docetaxel-resistant prostate cancer. Oncogene. 2024;43(26):2038\u20132050.","journal-title":"Oncogene"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2024.07.019"},{"issue":"1","key":"e_1_3_4_17_1","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1038\/s41467-021-22163-7","article-title":"SUMOylation controls the binding of hexokinase 2 to mitochondria and protects against prostate cancer tumorigenesis","volume":"12","author":"Shangguan X","year":"2021","unstructured":"Shangguan X, He J, Ma Z, Zhang W, Ji Y, Shen K, Yue Z, Li W, Xin Z, Zheng Q, et al. SUMOylation controls the binding of hexokinase 2 to mitochondria and protects against prostate cancer tumorigenesis. Nat Commun. 2021;12(1):1812.","journal-title":"Nat Commun"},{"issue":"1","key":"e_1_3_4_18_1","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12929-022-00797-z","article-title":"Combination treatment of docetaxel with caffeic acid phenethyl ester suppresses the survival and the proliferation of docetaxel-resistant prostate cancer cells via induction of apoptosis and metabolism interference","volume":"29","author":"Fu Y-K","year":"2022","unstructured":"Fu Y-K, Wang B-J, Tseng J-C, Huang S-H, Lin C-Y, Kuo Y-Y, Hour T-C, Chuu C-P. Combination treatment of docetaxel with caffeic acid phenethyl ester suppresses the survival and the proliferation of docetaxel-resistant prostate cancer cells via induction of apoptosis and metabolism interference. J Biomed Sci. 2022;29(1):16.","journal-title":"J Biomed Sci"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1089\/ars.2017.7350"},{"issue":"4","key":"e_1_3_4_20_1","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1111\/bjh.18684","article-title":"Proline promotes proliferation and drug resistance of multiple myeloma by downregulation of proline dehydrogenase","volume":"201","author":"Zhang J","year":"2023","unstructured":"Zhang J, Shi F, Liu X, Wu X, Hu C, Guo J, Yang Q, Xia J, He Y, An G, et al. Proline promotes proliferation and drug resistance of multiple myeloma by downregulation of proline dehydrogenase. Br J Haematol. 2023;201(4):704\u2013717.","journal-title":"Br J Haematol"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-023-02623-2"},{"key":"e_1_3_4_22_1","doi-asserted-by":"crossref","first-page":"942261","DOI":"10.3389\/fphar.2022.942261","article-title":"Exogenous proline enhances susceptibility of NSCLC to cisplatin via metabolic reprogramming and PLK1-mediated cell cycle arrest","volume":"13","author":"Han B","year":"2022","unstructured":"Han B, Sun Y, Zhang X, Yue P, Tian M, Yan D, Yin F, Qin B, Zhao Y. Exogenous proline enhances susceptibility of NSCLC to cisplatin via metabolic reprogramming and PLK1-mediated cell cycle arrest. Front Pharmacol. 2022;13:942261.","journal-title":"Front Pharmacol"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1021\/jasms.4c00445"},{"key":"e_1_3_4_24_1","first-page":"2025","article-title":"Survival and clinicopathological significance of PYCR1 expression in cancer: a meta-analysis","volume":"12","author":"Li Y","year":"2022","unstructured":"Li Y, Xu J, Bao P, Wei Z, Pan L, Zhou J, Wang W. Survival and clinicopathological significance of PYCR1 expression in cancer: a meta-analysis. Front Oncol. 2022;12:2025\u20132009. https:\/\/www.frontiersin.org\/journals\/oncology\/articles\/10.3389\/fonc.2022.985613\/full.","journal-title":"Front Oncol"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1080\/14756366.2025.2545620"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1080\/15384047.2025.2546219"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.70045"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/s42255-022-00582-0"},{"issue":"1","key":"e_1_3_4_29_1","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41392-024-01872-7","article-title":"Engineered extracellular vesicles for targeted reprogramming of cancer-associated fibroblasts to potentiate therapy of pancreatic cancer","volume":"9","author":"Zhou P","year":"2024","unstructured":"Zhou P, Du X, Jia W, Feng K, Zhang Y. Engineered extracellular vesicles for targeted reprogramming of cancer-associated fibroblasts to potentiate therapy of pancreatic cancer. Signal Transduct Target Ther. 2024;9(1):151.","journal-title":"Signal Transduct Target Ther"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13577-022-00775-5"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2022.154481"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-05905-z"},{"key":"e_1_3_4_33_1","doi-asserted-by":"crossref","first-page":"102829","DOI":"10.1016\/j.sbi.2024.102829","article-title":"Structure-based virtual screening of vast chemical space as a starting point for drug discovery","volume":"87","author":"Carlsson J","year":"2024","unstructured":"Carlsson J, Luttens A. Structure-based virtual screening of vast chemical space as a starting point for drug discovery. Curr Opin Struct Biol. 2024;87:102829.","journal-title":"Curr Opin Struct Biol"},{"issue":"5","key":"e_1_3_4_34_1","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3892\/ijo.2024.5691","article-title":"Emodin inhibits benzidine\u2011enhanced survival and migration of upper urinary tract urothelial carcinoma cells by targeting the PKA\/COX2 signaling pathway","volume":"65","author":"Jin Y","year":"2024","unstructured":"Jin Y, Wang C, Feng K, Wang X, Tong M, Tong G. Emodin inhibits benzidine\u2011enhanced survival and migration of upper urinary tract urothelial carcinoma cells by targeting the PKA\/COX2 signaling pathway. Int J Oncol. 2024;65(5):103.","journal-title":"Int J Oncol"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2024.156247"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-024-03758-5"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2025.156958"},{"issue":"1","key":"e_1_3_4_38_1","doi-asserted-by":"crossref","first-page":"13398","DOI":"10.1038\/s41598-023-40160-2","article-title":"Molecular docking as a tool for the discovery of molecular targets of nutraceuticals in diseases management","volume":"13","author":"Agu PC","year":"2023","unstructured":"Agu PC, Afiukwa CA, Orji OU, Ezeh EM, Ofoke IH, Ogbu CO, Ugwuja EI, Aja PM. Molecular docking as a tool for the discovery of molecular targets of nutraceuticals in diseases management. Sci Rep. 2023;13(1):13398.","journal-title":"Sci Rep"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2023.154862"},{"key":"e_1_3_4_40_1","doi-asserted-by":"crossref","first-page":"115968","DOI":"10.1016\/j.jep.2022.115968","article-title":"Aidi injection enhances the anti-tumor impact of doxorubicin in H22 tumor-containing mice","volume":"303","author":"Lu Y","year":"2023","unstructured":"Lu Y, Zhang S, Zhu X, Wang K, He Y, Liu C, Sun J, Pan J, Zheng L, Liu W, et al. Aidi injection enhances the anti-tumor impact of doxorubicin in H22 tumor-containing mice. J Ethnopharmacol. 2023;303:115968.","journal-title":"J Ethnopharmacol"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkaa407"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26157119"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-06200-5"},{"issue":"12","key":"e_1_3_4_44_1","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1038\/s42255-023-00919-3","article-title":"Inhibition of the proline metabolism rate-limiting enzyme P5CS allows proliferation of glutamine-restricted cancer cells","volume":"5","author":"Linder SJ","year":"2023","unstructured":"Linder SJ, Bernasocchi T, Mart\u00ednez-Pastor B, Sullivan KD, Galbraith MD, Lewis CA, Ferrer CM, Boon R, Silveira GG, Cho HM, et al. Inhibition of the proline metabolism rate-limiting enzyme P5CS allows proliferation of glutamine-restricted cancer cells. Nat Metab. 2023;5(12):2131\u20132147.","journal-title":"Nat Metab"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1080\/14756366.2024.2367129"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-06893-9"},{"issue":"1","key":"e_1_3_4_47_1","doi-asserted-by":"crossref","first-page":"27382","DOI":"10.1038\/srep27382","article-title":"Docetaxel induced-JNK2\/PHD1 signaling pathway increases degradation of HIF-1\u03b1 and causes cancer cell death under hypoxia","volume":"6","author":"Oh E-T","year":"2016","unstructured":"Oh E-T, Kim CW, Kim SJ, Lee J-S, Hong S-S, Park HJ. Docetaxel induced-JNK2\/PHD1 signaling pathway increases degradation of HIF-1\u03b1 and causes cancer cell death under hypoxia. Sci Rep. 2016;6(1):27382.","journal-title":"Sci Rep"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23158510"},{"issue":"22","key":"e_1_3_4_49_1","doi-asserted-by":"crossref","first-page":"13738","DOI":"10.3390\/ijms232213738","article-title":"Cell metabolomics reveals the potential mechanism of aloe emodin and emodin inhibiting breast cancer metastasis","volume":"23","author":"Cheng G","year":"2022","unstructured":"Cheng G, Liu Z, Zheng Z, Song F, Zhuang X, Liu S. Cell metabolomics reveals the potential mechanism of aloe emodin and emodin inhibiting breast cancer metastasis. Int J Mol Sci. 2022;23(22):13738.","journal-title":"Int J Mol Sci"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2019.172525"},{"issue":"9","key":"e_1_3_4_51_1","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1007\/s10495-024-01973-2","article-title":"Emodin induces ferroptosis in colorectal cancer through NCOA4-mediated ferritinophagy and NF-\u03bab pathway inactivation","volume":"29","author":"Shen Z","year":"2024","unstructured":"Shen Z, Zhao L, Yoo S-A, Lin Z, Zhang Y, Yang W, Piao J. Emodin induces ferroptosis in colorectal cancer through NCOA4-mediated ferritinophagy and NF-\u03bab pathway inactivation. Apoptosis. 2024;29(9\u201310):1810\u20131823.","journal-title":"Apoptosis"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2021.153786"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2024.116578"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1002\/med.22079"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules28134931"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1002\/med.21739"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2024.104161"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpx.2024.100314"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-016-2010-5"},{"key":"e_1_3_4_60_1","doi-asserted-by":"crossref","first-page":"121176","DOI":"10.1016\/j.biomaterials.2021.121176","article-title":"Prodrug nanoparticles rationally integrating stroma modification and chemotherapy to treat metastatic pancreatic cancer","volume":"278","author":"Wang L","year":"2021","unstructured":"Wang L, Liu Z, Zhou Q, Gu S, Liu X, Huang J, Jiang H, Wang H, Cao L, Sun J, et al. Prodrug nanoparticles rationally integrating stroma modification and chemotherapy to treat metastatic pancreatic cancer. Biomaterials. 2021;278:121176.","journal-title":"Biomaterials"},{"key":"e_1_3_4_61_1","doi-asserted-by":"crossref","first-page":"100449","DOI":"10.1016\/j.mtbio.2022.100449","article-title":"Tumor-targeted dual-starvation therapy based on redox-responsive micelle nanosystem with co-loaded LND and BPTES","volume":"16","author":"Fu Z","year":"2022","unstructured":"Fu Z, Du H, Meng S, Yao M, Zhao P, Li X, Zheng X, Yuan Z, Yang H, Cai K, et al. Tumor-targeted dual-starvation therapy based on redox-responsive micelle nanosystem with co-loaded LND and BPTES. Mater Tod Bio. 2022;16:100449.","journal-title":"Mater Tod Bio"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S474158"},{"issue":"12","key":"e_1_3_4_63_1","doi-asserted-by":"crossref","first-page":"5955","DOI":"10.7150\/thno.58164","article-title":"Enhanced anti-PD-1 therapy in hepatocellular carcinoma by tumor vascular disruption and normalization dependent on combretastatin A4 nanoparticles and DC101","volume":"11","author":"Bao X","year":"2021","unstructured":"Bao X, Shen N, Lou Y, Yu H, Wang Y, Liu L, Tang Z, Chen X. Enhanced anti-PD-1 therapy in hepatocellular carcinoma by tumor vascular disruption and normalization dependent on combretastatin A4 nanoparticles and DC101. Theranostics. 2021;11(12):5955\u20135969.","journal-title":"Theranostics"},{"key":"e_1_3_4_64_1","doi-asserted-by":"crossref","first-page":"101667","DOI":"10.1016\/j.tranon.2023.101667","article-title":"PYCR1 promotes the malignant progression of lung cancer through the JAK\u2013STAT3 signaling pathway via PRODH-dependent glutamine synthesize","volume":"32","author":"Zhang L","year":"2023","unstructured":"Zhang L, Zhao X, Wang E, Yang Y, Hu L, Xu H, Zhang B. PYCR1 promotes the malignant progression of lung cancer through the JAK\u2013STAT3 signaling pathway via PRODH-dependent glutamine synthesize. Transl Oncol. 2023;32:101667.","journal-title":"Transl Oncol"},{"issue":"8","key":"e_1_3_4_65_1","first-page":"3780","article-title":"PYCR1 regulates glutamine metabolism to construct an immunosuppressive microenvironment for the progression of clear cell renal cell carcinoma","volume":"12","author":"Wei X","year":"2022","unstructured":"Wei X, Zhang X, Wang S, Wang Y, Ji C, Yao L, Song N. PYCR1 regulates glutamine metabolism to construct an immunosuppressive microenvironment for the progression of clear cell renal cell carcinoma. Am J Cancer Res. 2022;12(8):3780\u20133798.","journal-title":"Am J Cancer Res"}],"container-title":["Journal of Enzyme Inhibition and Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14756366.2026.2622725","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T11:44:11Z","timestamp":1770723851000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14756366.2026.2622725"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,10]]},"references-count":64,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12,31]]}},"alternative-id":["10.1080\/14756366.2026.2622725"],"URL":"https:\/\/doi.org\/10.1080\/14756366.2026.2622725","relation":{},"ISSN":["1475-6366","1475-6374"],"issn-type":[{"value":"1475-6366","type":"print"},{"value":"1475-6374","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,10]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ienz20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ienz20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-10-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-19","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"2622725"}}